WATERTOWN, Mass., Oct. 31, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying ...
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...
WORCESTER, Mass.—Making a movie at the molecular level? A new method of imaging molecule-sized machines as they do the complex work of cutting and pasting genetic information inside the nucleus is the ...
Akari Therapeutics plc has released preclinical data demonstrating the potential of its novel antibody-drug conjugate (ADC) spliceosome modulating payload, PH1, for the treatment of tumors driven by ...
Alternative splicing, a clever way a cell generates many different variations of messenger RNAs -- single-stranded RNAs involved in protein synthesis -- and proteins from the same stretch of DNA, ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 48 (November 29, 2022), pp. 1-12 (12 pages) Spliceosome activation is the process of creating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback